Razavi Alexander C, Reyes Mikaila P, Wilkins John T, Szklo Moyses S, Tsai Michael Y, Whelton Seamus P, Sperling Laurence S, Tsimikas Sotirios, Bhatia Harpreet S
Emory Clinical Cardiovascular Research Institute, Emory University School of Medicine, Atlanta, GA, USA.
School of Medicine, University of California San Diego, La Jolla, CA.
Eur J Prev Cardiol. 2024 Nov 28. doi: 10.1093/eurjpc/zwae382.
To assess the association of traditional risk factor burden and Life's Simple 7 (LS7) score with incident atherosclerotic cardiovascular disease (ASCVD) across Lp(a) levels.
There were 6,676 participants without clinical ASCVD from the Multi-Ethnic Study of Atherosclerosis who underwent Lp(a) testing and were followed for incident ASCVD events (coronary heart disease and stroke). Low, intermediate, and elevated Lp(a) were defined as <30, 30-49, and >50 mg/dL, respectively. Cox proportional hazards regression assessed the association of traditional risk factors and LS7 score (poor: 0-8, average: 9-10, optimal: 11-14) with incident ASCVD across Lp(a) groups during a median follow-up of 17.7 years, adjusting for demographics and time-varying statin and aspirin therapy.
The mean age was 62.1 years, 53% were women, and 61% were non-white. The median Lp(a) was 17 (IQR 8-41) mg/dL, 13% had Lp(a) 30-49 mg/dL, and 20% had Lp(a) >50 mg/dL. Individuals with Lp(a) >50 mg/dL had higher absolute event rates across all LS7 categories. There was no significant interaction between Lp(a) and LS7 score on incident ASCVD (p-interaction=0.60). Compared to a poor LS7 score, optimal LS7 conferred a lower risk for incident ASCVD among individuals with Lp(a) <30 (HR=0.45, 95% CI: 0.28-0.71), Lp(a) 30-49 (HR=0.12, 95% CI: 0.02-0.89), and Lp(a) >50 mg/dL (HR=0.35, 95% CI: 0.13-0.99).
Participants without clinical ASCVD who achieved an optimal LS7 score had ASCVD risk reduction regardless of Lp(a) level. These results emphasize the importance of a healthy lifestyle and ASCVD risk factor control among individuals with elevated Lp(a).
评估传统危险因素负担和生命简单七项(LS7)评分与不同Lp(a)水平下动脉粥样硬化性心血管疾病(ASCVD)发生风险之间的关联。
来自动脉粥样硬化多族裔研究的6676名无临床ASCVD的参与者接受了Lp(a)检测,并对其ASCVD事件(冠心病和中风)进行随访。低、中、高Lp(a)分别定义为<30、30 - 49和>50 mg/dL。Cox比例风险回归分析在17.7年的中位随访期内,评估传统危险因素和LS7评分(差:0 - 8分,中等:9 - 10分,最佳:11 - 14分)与不同Lp(a)组ASCVD发生风险之间的关联,并对人口统计学因素以及随时间变化的他汀类药物和阿司匹林治疗进行校正。
平均年龄为62.1岁,53%为女性,61%为非白人。Lp(a)中位数为17(四分位间距8 - 41)mg/dL,13%的Lp(a)为30 - 49 mg/dL,20%的Lp(a)>50 mg/dL。Lp(a)>50 mg/dL的个体在所有LS7类别中绝对事件发生率更高。Lp(a)与LS7评分在ASCVD发生风险上无显著交互作用(交互作用p值 = 0.60)。与LS7评分差相比,最佳LS7评分使Lp(a)<30(风险比[HR]=0.45,95%置信区间[CI]:0.28 - 0.71)、Lp(a) 30 - 49(HR = 0.12,95% CI:0.02 - 0.89)和Lp(a)>50 mg/dL(HR = 0.35,95% CI:0.13 - 0.99)的个体发生ASCVD的风险降低。
无临床ASCVD且达到最佳LS7评分的参与者,无论Lp(a)水平如何,其ASCVD风险均降低。这些结果强调了Lp(a)升高个体保持健康生活方式和控制ASCVD危险因素的重要性。